Claims for Patent: 10,231,665

Summary for Patent: 10,231,665

Title:	Diagnosing and treating movement disorders
Abstract:	A system for obtaining and analyzing data for overall joint motion from a plurality of joints of a subject experiencing a movement disorder involves a plurality of kinematic sensors configured to be placed on a body of a subject experiencing a movement disorder proximal a plurality of joints of the subject. The kinematic sensors are selected to measure overall joint motion with sufficient degrees of freedom for individual joints so that data collected by the sensors can be deconstructed into multiple degrees of freedom for individual joints and analyzed to provide amplitude of the movements caused by the movement disorder and/or relative contributions from and/or directional bias for each muscle group that may be implicated in the movement of each joint. Such a system permits methods for determining a treatment regimen for treating the movement disorder, whereby the treatment regimen is based on the amplitude of the movements and/or the relative contribution and/or directional bias of each muscle group to the movements caused by the movement disorder.
Inventor(s):	Rahimi; Fariborz (Kitchener, CA), Jog; Mandar (London, CA)
Assignee:
Application Number:	14/914,591
Patent Claims:	1. A method of obtaining a treatment regimen for treating a movement disorder in a subject, the method comprising: obtaining sensor data for overall joint motion collected from kinematic sensors placed at a plurality of joints of a subject having a movement disorder, the kinematic sensors comprising at least one goniometer, or at least one accelerometer, at least one gyroscope and at least one electromagnetometer, the kinematic sensors placed at selected locations and in sufficient number to measure the motion at each joint independently along multiple degrees of freedom; using a computer to deconstruct the sensor data into the multiple degrees of freedom for individual joints and obtaining amplitude of the movements caused by the movement disorder, relative contributions from each of the muscle groups implicated in the movements of the individual joints and directional bias of each of the muscle groups involved in the movements caused by the movement disorder from the multiple degrees of freedom, the deconstructing and/or obtaining amplitude, relative contributions and directional bias accomplished by computer executable instructions therefor stored in a non-transient, physical memory device; and, obtaining a personalized treatment regimen for the subject from the amplitude of the movements, the relative contributions from each of the muscle groups implicated in the movements of the individual joints and the directional bias of each muscle group to the movements caused by the movement disorder, the personalized treatment regimen comprising administering a drug to one or more muscles of the muscle groups of the subject involved in the movements caused by the movement disorder, wherein the amplitude of the movements is used to provide total dosage of the drug to be administered to the subject, the relative contributions of the muscle groups is used to provide a proportion of the total dosage to be administered to each muscle group and the directional bias of the muscle groups is used to provide a sub-proportion of the drug to administer to each individual muscle implicated in the movements of the individual joints. 2. The method according to claim 1, wherein the treatment regimen comprises an injectable treatment regimen and/or a non-injectable treatment regimen, the injectable treatment regimen comprising injecting a drug or mixture of drugs and the non-injectable treatment regimen comprising electromagnetic (e/m) radiation therapy, electromyogram stimulator, functional electrical stimulation, active orthotic device, ultrasound therapy, acupuncture, trans-cranial magnetic stimulation or topical application of drugs. 3. The method according to claim 1, wherein the drug comprises a Botulinum toxin. 4. The method according to claim 1, wherein the drug comprises Botulinum toxin type A (BoNT A) or Botulinum toxin type B (BoNT B). 5. The method according to claim 1, wherein the drug is administered by injection. 6. The method according to claim 1, wherein the treatment regimen is optimized after a first administration of the drug by analyzing the deconstructed sensor data for each joint of the subject, the muscles and drug dosages selected for the first administration of the drug, and outcome of the subject after the first administration of the drug to determine adjustments to be made to location and dosage of drug administration in a second administration of the drug. 7. The method according to claim 6, wherein the outcome of the subject comprises the subject developing a weakness in one or more muscles as a result of the first administration of the drug, and wherein the regimen is optimized by reducing the dosage of the drug to the one or more muscles that developed the weakness. 8. The method according to claim 7, wherein the outcome of the subject comprises an insufficient reduction in the amplitude of the movements caused by the movement disorder at a given joint and a change of 10% or more in the muscle composition of the movements caused by the movement disorder at the given joint, and wherein the regimen is optimized by increasing the dosage of the drug to the muscle group that has become the most dominant contributor to the movement caused by the movement disorder at the given joint, provided that the muscle group receiving the increased dosage of the drug does not comprise one or more of the one or more muscles that developed the weakness. 9. The method according to claim 8, wherein the regimen is optimized by asking the subject whether the movement disorder has improved, and if the subject reports that the movement disorder has not improved then increasing the dosage of the drug at each muscle that was previously dosed without dosing muscles that were not previously dosed with the drug, provided that the dosage of the drug is not increased in any muscle that developed the weakness or any muscle that is receiving an increased dosage of the drug under conditions defined in claim 8. 10. The method according to claim 1, wherein the movement disorder is Parkinson's disease (PD) or essential tremor (ET) or spasticity. 11. The method according to claim 1, wherein the muscle groups comprise one or more of flexion-extensor (F/E) muscles, ulnar-radial (U/R) muscles, abduction/adduction (A/A) muscles, and pronation-supination (P/S) muscles. 12. The method according to claim 1, wherein the movement disorder is Parkinson's disease (PD) or essential tremor (ET) or spasticity. 13. The method according to claim 12, wherein the drug comprises Botulinum toxin type A (BoNT A) or Botulinum toxin type B (BoNT B). 14. The method according to claim 12, wherein the muscle groups comprise one or more of abduction/adduction (A/A) muscles, flexion-extensor (F/E) muscles, ulnar-radial (U/R) muscles and pronation-supination (P/S) muscles. 15. The method according to claim 1, further comprising administering the drug to the subject in accordance with the personalized treatment regimen. 16. A method for treating a movement disorder in a subject, the method comprising: obtaining sensor data for overall joint motion collected from kinematic sensors placed at a plurality of joints of a subject having a movement disorder, the kinematic sensors measuring the motion at each joint independently along multiple degrees of freedom; using a computer to deconstruct the sensor data into the multiple degrees of freedom for individual joints and obtaining amplitude of the movements caused by the movement disorder, relative contributions from each of the muscle groups implicated in the movements of the individual joints and directional bias of each of the muscle groups involved in the movements caused by the movement disorder from the multiple degrees of freedom, the deconstructing and/or obtaining amplitude, relative contributions and directional bias accomplished by computer executable instructions therefor stored in a non-transient, physical memory device; obtaining a personalized treatment regimen for the subject from the amplitude of the movements, the relative contributions from each of the muscle groups implicated in the movements of the individual joints and the directional bias of each muscle group to the movements caused by the movement disorder, the personalized treatment regimen comprising administering a drug to one or more muscles of the muscle groups of the subject involved in the movements caused by the movement disorder, wherein the amplitude of the movements is used to provide total dosage of the drug to be administered to the subject, the relative contributions of the muscle groups is used to provide a proportion of the total dosage to be administered to each muscle group and the directional bias of the muscle groups is used to provide a sub-proportion of the drug to administer to each individual muscle implicated in the movements of the individual joints; and, administering the drug to the subject in accordance with the personalized treatment regimen.

Details for Patent 10,231,665

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000		2033-09-20